Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction.

Rian Dickstein is an Urologist in Baltimore, Maryland. Dr. Dickstein is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Hydronephrosis, Ureteroscopy, and Nephrectomy. Dr. Dickstein is currently accepting new patients.

Nirmish Singla is an Oncologist in Lutherville, Maryland. Dr. Singla is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Orchiectomy.

Jonathan Rhee is an Urologist in Silver Spring, Maryland. Dr. Rhee is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are UPJ Obstruction, Bilateral Hydronephrosis, Hydronephrosis, Ureteroscopy, and Prostatectomy. Dr. Rhee is currently accepting new patients.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Sunil H. Patel, M.D., M.A., is an Assistant Professor of Urology and Oncology at the School of Medicine at Johns Hopkins. He serves as and the Director of the Urologic Oncology Fellowship. He also serves as Director of the Testicular Cancer program. He treats all urologic malignancies, including adrenal cancer, kidney cancer, urothelial cancer, bladder cancer, prostate cancer, testes cancer, and penile cancers. Additionally, he has advanced training in complex robotic and open surgical cases. His clinical and research focus is in Urologic Oncology, with areas of focus in bladder cancer, testes cancer, and kidney cancer. Dr. Patel completed his undergraduate studies at California Polytechnic State University, San Luis Obispo where he studied Biological Sciences. He completed his Masters at Boston University, completing his thesis on microfluidics, afterwards completing his medical degree at Boston University. He completed his general surgery internship and urology residency at University of California, San Diego. He continued his training through a Society of Urologic Oncology Fellowship in urologic oncology at the Johns Hopkins Hospital. He joined Johns Hopkins in June 2020 with interests in environmental factors contributing to oncogenesis in urological cancers, especially bladder cancer. He is dedicated to international health and works closely with international volunteers in urology and has done several mission trips and guest lectures. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Peter Filderman is an Urologist in Baltimore, Maryland. Dr. Filderman is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), UPJ Obstruction, Urinary Tract Infection in Children, Ureteroscopy, and Bladder Reconstruction.

Frank Nezu is an Urologist in Columbia, Maryland. Dr. Nezu is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), Perirenal Abscess, Carbuncle, Boils, and Ureteroscopy.

Dr. Kathleen Sterling is part of the Suburban Hospital’s medical staff and a urologist with Urological Consultants, P.A. Dr. Sterling served as chief resident of the University of Maryland Medical Center urology program. During her training, she performed laboratory research related to overactive bladder. With an undergraduate degree from Vanderbilt University, Dr. Sterling served as a Surface Warfare Officer in the United States Navy, completing two deployments at sea, including one combat mission during Operation Iraqi Freedom. Dr. Sterling treats both men and women. Her expertise includes voiding dysfunction, male and female urinary incontinence and female pelvic floor disorders. Dr. Sterling’s practice also encompasses medical and surgical management of kidney stones, erectile dysfunction and urological cancers. Dr. Sterling sees patients in Bethesda and Germantown, Maryland. For appointments, call 301-530-1700. Dr. Sterling is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Urinary Incontinence, Kidney Stones, and Ureteroscopy.

Alejandro Rodriguez is an Urologist in Columbia, Maryland. Dr. Rodriguez is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), UPJ Obstruction, Kidney Stones, Familial Prostate Cancer, and Ureteroscopy.

Dr. Kenneth Pienta is the Donald S. Coffey Professor of Urology and a professor of oncology at the Johns Hopkins School of Medicine. He also holds an appointment in the department of pharmacology and molecular sciences. He is an internationally recognized leader in prostate cancer research and translational science. Dr. Pienta serves as the director of research for the Brady Urological Institute and co-leader of the Kimmel Cancer Center's Prostate Cancer Program. Dr. Pienta has a proven, peer-reviewed track record in organizing and administering a translational research program that successfully incorporates bench research, agent development and clinical application. He has international expertise in the development of novel chemotherapeutic programs for prostate cancer and has championed the concept that translational research is often best accomplished by multi-disciplinary teams of scientists and clinicians. Under his direction, the success of these endeavors led to the receipt of the first annual American Association for Cancer Research Team Science Award in 2007. Dr. Pienta received his B.A. in human biology from the Johns Hopkins University. He earned his M.D. from the Johns Hopkins School of Medicine. He completed his residency at the University of Chicago Hospitals and Clinics and performed a fellowship in oncology at The Johns Hopkins Hospital. Prior to joining Johns Hopkins, Dr. Pienta was the associate vice president for research, health sciences for the University of the Michigan from 2012 to 2013 and director of precision medicine for the Michigan Center for Translational Pathology from 2008 to 2013. He joined the Johns Hopkins faculty in 2013. Dr. Pienta's research interests include the ecology of cancer, tumor microenvironment, metastasis, biomarker development and novel therapeutic development. Dr. Pienta is a two-time American Cancer Society Clinical Research Professor Award recipient. He holds several patents, has authored more than 350 peer-reviewed articles and has been the principle investigator on numerous local and national clinical trials. Dr. Pienta is currently actively developing clinical trials and treating patients with newly diagnosed high risk and metastatic prostate cancer. Dr. Pienta is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Bone Tumor, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

Kasey Morrison is an Urologist in Silver Spring, Maryland. Dr. Morrison has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Neurogenic Bladder, Bilateral Hydronephrosis, Hydronephrosis, Ureteroscopy, and Prostatectomy. Dr. Morrison is currently accepting new patients.

Md Siddiqui is a Hematologist Oncology specialist and a Hematologist in Salisbury, Maryland. Dr. Siddiqui is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Pulmonary Embolism, Inflammatory Breast Cancer, Angiosarcoma, and Childhood Iron Deficiency Anemia. Dr. Siddiqui is currently accepting new patients.

Kent Krejci is an Urologist and a Rheumatologist in Bowie, Maryland. Dr. Krejci is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Krejci is currently accepting new patients.

David Mcdermott is an Urologist and a General Surgeon in Bowie, Maryland. Dr. Mcdermott is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Congenital Mesoblastic Nephroma, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Mcdermott is currently accepting new patients.

Christopher Runz is an Urologist in Centreville, Maryland. Dr. Runz is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are UPJ Obstruction, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Ureteroscopy, and Prostatectomy. Dr. Runz is currently accepting new patients.

Mohummad Siddiqui is an Urologist in Baltimore, Maryland. Dr. Siddiqui is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Vasectomy, and Nephrectomy. Dr. Siddiqui is currently accepting new patients.

Mark Shimko is an Urologist in Baltimore, Maryland. Dr. Shimko is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, UPJ Obstruction, Nephrectomy, and Reconstructive Urology Surgery. Dr. Shimko is currently accepting new patients.